eligibility_summary
Eligibility: Adults 18–70 with advanced solid tumors: tumor MSLN membrane≥50%, MUC1≥50%, PD‑L1+, failed/intolerant to standard therapy, ECOG 0–1, life >3 mo, RECIST‑measurable, adequate organ/marrow function, consent and contraception. Exclude: recent anti‑cancer therapy, prior gene/T‑cell therapy, pregnancy, active HBV/HCV/HIV/syphilis, uncontrolled infection/coagulopathy, autoimmune/transplant or immunosuppression, major cardiac/pulmonary/CNS disease, high bleeding risk, recent major surgery/trauma, other active cancer.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Fast CAR T cells—autologous, gene‑modified T cells made with a non‑viral vector, dose-escalation (5×10^5, 1×10^6, 5×10^6 cells/kg). Mechanism/type: Multi‑targeted CAR‑T therapy engineered to recognize mesothelin and MUC1 on tumor cells and to auto‑secrete multifunctional antibodies, aiming to enhance antitumor immunity within the tumor microenvironment. Cells/pathways targeted: Tumor cells expressing mesothelin and MUC1, activation of T‑cell cytotoxic signaling via CAR (CD3ζ and costimulatory domains) against these antigens, secreted antibodies intended to modulate immunosuppressive pathways in the tumor microenvironment (e.g., checkpoint or cytokine milieu). Population: Advanced solid tumors with mesothelin ≥50%, MUC1 ≥50%, and PD‑L1 positive. Primary aim: safety/tolerability. Location: China. Status: Recruiting.